Butterfly-Shaped Pattern Dystrophy

Butterfly-shaped pattern dystrophy is a rare, inherited eye condition that mainly affects the macula, the sharp-vision center of the retina. In this condition, tiny waste products (mostly the pigment lipofuscin) build up in the retinal pigment epithelium (RPE). On exam, the deposits form dark and light lines that look like the wings of a butterfly across the macula. Vision can be normal for many years. Later, people may notice mild blur, waviness of lines, or trouble reading, especially in middle age or beyond. The disease is usually slowly progressive and often runs in families in an autosomal dominant pattern (you only need one changed gene copy to be affected). The most frequently involved gene is PRPH2 (also known as RDS), which helps build and stabilize the outer segments of photoreceptors; less commonly, variants in CTNNA1 are reported. Distinguishing this condition from age-related macular degeneration (AMD) is important because the outlook and management differ. Characteristic tests include color fundus photos, fundus autofluorescence (FAF), optical coherence tomography (OCT), and sometimes fluorescein angiography; electrodiagnostic testing is often normal or only mildly abnormal. Orpha+4EyeWiki+4NCBI+4

Butterfly-shaped pattern dystrophy is a rare, inherited macular condition in which pigment and waste products (mostly lipofuscin) collect in a butterfly-like pattern at the level of the retinal pigment epithelium (RPE) in both eyes. People usually notice mild central blur, distortion, or glare in mid-to-late adulthood, and many keep useful vision for years. The disorder belongs to the “pattern dystrophies,” a family of diseases that mostly involve the RPE, often linked to variants in the PRPH2 (also called RDS) gene. On clinical exam and imaging (fundus photos and autofluorescence), BPD shows 3–5 “wings” of pigment at the macula; OCT helps show RPE/photoreceptor changes, and the overall outlook is often better than many retinal degenerations, though some patients develop complications such as choroidal neovascularization (CNV). NCBI+2EyeWiki+2

The PRPH2 protein helps build and stabilize the outer parts of rod and cone cells. When PRPH2 is altered, the outer segments and their relationship with the RPE are disturbed, so visual cycle by-products aren’t cleared efficiently and accumulate as lipofuscin. This makes the macular RPE look patterned and can slowly disturb central vision. BPD is usually autosomal dominant, so a parent with the variant can pass it to a child with a 50% chance; sometimes the gene change occurs for the first time in a family. MedlinePlus+2PMC+2

---

Other (Alternative) Names

People and papers may use several names for the same condition. These mean the same or very similar things:

• Butterfly-shaped pigment dystrophy

• Butterfly-shaped pattern dystrophy of the macula

• Pattern dystrophy of the retinal pigment epithelium (RPE) – butterfly type

• Pattern macular dystrophy – butterfly subtype

All of these terms point to a patterned, butterfly-like distribution of RPE pigment change in the macula due to inherited factors. EyeWiki+2PentaVision+2

---

Types

“Pattern dystrophies” are a family of closely related macular conditions. The butterfly form is one subtype. Other classic subtypes help doctors think about the range of appearances and can overlap in families with the same gene change:

1. Butterfly-shaped pattern dystrophy (the focus here). The macular pigment forms “butterfly wings.” FAF shows a central pattern of mixed hyper- and hypo-autofluorescence. OCT often shows RPE irregularity with relatively preserved retinal thickness. EyeWiki+1

2. Adult-onset foveomacular vitelliform dystrophy. A small, round yellow “egg-yolk” deposit under the fovea; can occur in the same families. EyeWiki

3. Multifocal pattern dystrophy simulating fundus flavimaculatus. Scattered yellow-white flecks that can resemble ABCA4-related disease, but genetics and course differ. EyeWiki

4. Reticular dystrophy. A net-like (reticular) pigment pattern across the posterior pole. EyeWiki

5. Fundus pulverulentus. Speckled, dust-like RPE changes within the macula. EyeWiki

Key idea: these patterns often share PRPH2 involvement and autosomal dominant inheritance, and different subtypes can appear in different relatives with the same pathogenic variant. EyeWiki+1

---

Causes

In this condition, “causes” mostly means genetic causes and modifiers. Environmental factors may influence the appearance or progression, but the core driver is inherited.

1. PRPH2 (RDS) pathogenic variants. The most established cause; PRPH2 encodes peripherin-2, essential for photoreceptor outer segments. When changed, RPE/photoreceptor interaction fails and lipofuscin builds up in patterns. MedlinePlus+1

2. CTNNA1 variants (alpha-catenin). Less common, but proven in families with classic butterfly-shaped lesions, supporting genetic heterogeneity. PMC

3. Autosomal dominant inheritance. One changed copy is enough. Family history is common, though expression may vary. EyeWiki

4. Photoreceptor–RPE structural instability. Faulty peripherin-2 alters the outer segment discs, stressing the RPE and promoting pigment/lipofuscin patterning. MedlinePlus

5. Lipofuscin accumulation in RPE. This natural by-product of visual cycle builds up faster when RPE stress is present, creating the butterfly pattern seen on FAF. Orpha+1

6. Variable expressivity of the same variant. Even within one family, different patterns (butterfly, reticular, vitelliform) can occur, reflecting modifiers we do not fully understand. PentaVision

7. Age-related expression. Many people are asymptomatic until mid-life, implying time-dependent accumulation. rarediseases.info.nih.gov

8. Incomplete penetrance. Some carriers show mild changes or none on routine exam, but FAF or genetics reveal disease. PMC

9. Oxidative stress load (speculative modifier). The RPE handles oxidative by-products; stress may unmask or accelerate visible changes in genetically predisposed people. (General mechanism noted across RPE lipofuscin disorders.) ScienceDirect

10. Light exposure over a lifetime (possible modifier). Cumulative light may influence lipofuscin dynamics in vulnerable RPE, though evidence is indirect. ScienceDirect

11. RPE–Bruch’s membrane changes. Subtle support-tissue changes may shape how pigment patterns form in the macula. AAO Journal

12. Genetic background beyond PRPH2/CTNNA1. Other IRD genes rarely mimic pattern dystrophy; broad panels sometimes find additional contributors. NCBI

13. Variant type (missense vs others). Different PRPH2 variants map to a wide spectrum of phenotypes, from pattern dystrophy to cone-rod dystrophy. PMC+1

14. Digenic or dual-gene effects (rare). Interactions with ROM1 and other disc-structure genes have been discussed in PRPH2 literature for broader IRD phenotypes. ScienceDirect

15. Metabolic handling of visual cycle by-products. When the RPE cannot clear these efficiently, deposits form visible patterns. ScienceDirect

16. Macular anatomy (foveal concentration of cones). The pattern centers on the macula, where cone density and RPE demand are highest. EyeWiki

17. Mild chronic inflammation signal (hypothesized). Low-grade stress pathways may contribute to pigment clumping; evidence is indirect from histopathology. ResearchGate

18. Genetic modifiers affecting autofluorescence. Differences in how eyes process and store lipofuscin may shape FAF patterns between individuals. ScienceDirect

19. Choroidal perfusion factors. Macular blood-supply differences may influence where deposits appear or clear. MDPI

20. Natural disease evolution over decades. The “butterfly” can sharpen, fade, or change with time as RPE pigment redistributes. EyeWiki

---

Symptoms

1. No symptoms for years. Many people feel nothing until middle age because changes start small. rarediseases.info.nih.gov

2. Mild blurred central vision. Letters look a bit fuzzy or washed out—often the first noticed problem. EyeWiki

3. Metamorphopsia (wavy lines). Straight lines may look bent on reading or on an Amsler grid. NCBI

4. Difficulty reading small print. The central retina does most reading work; subtle macular changes make this harder. EyeWiki

5. Reduced contrast sensitivity. Dark-on-gray or low-contrast text becomes harder to see. NCBI

6. Glare or light sensitivity. Bright light may reduce clarity temporarily. NCBI

7. Color perception changes (mild). Colors may look slightly dull or altered over time. NCBI

8. Central scotoma (small blind spot). A faint spot can develop in the center if RPE/photoreceptors are damaged. NCBI

9. Slow adaptation to dark. Moving from bright to dim rooms may feel harder. NCBI

10. Photopsias (brief flashes). Some notice tiny flickers in the central field. NCBI

11. Stable or very slowly progressive course. Many maintain good acuity for years; some worsen slowly. rarediseases.info.nih.gov

12. Occasional sudden drop if complications occur. Rarely, choroidal neovascularization (CNV) or atrophy can cause quicker loss. EyeWiki

13. Reading fatigue. Tasks needing fine central vision feel tiring. NCBI

14. Asymmetry between eyes. One eye may be more affected than the other at a given time. EyeWiki

15. Family members with similar issues. Relatives may report mild central blur or prior “macular changes” diagnoses. EyeWiki

---

Diagnostic Tests

A) Physical Examination (what the clinician does in clinic)

1. Best-corrected visual acuity (charts). Measures how clearly you see. Many have near-normal acuity early; mild reduction appears later. This helps track change over time. NCBI

2. Amsler grid at the chair. A simple grid to check for wavy or missing lines that suggest macular disturbance. NCBI

3. Pupil and anterior-segment exam. Rules out front-of-eye issues that might confuse the picture; the front is usually normal here. NCBI

4. Dilated fundus examination. The doctor looks at the macula with lenses and lights; the butterfly pattern appears as dark and light RPE lines spreading from the center. EyeWiki

5. In-office color plates (basic color vision). Quick screen for color changes that can accompany macular disease. NCBI

B) Manual / Functional Tests (simple tools or performance measures)

6. Near-vision reading tests. Reveal central blur impacting reading speed and endurance. NCBI

7. Contrast sensitivity charts. Detect reduced ability to see low-contrast patterns—a sensitive marker of macular dysfunction. NCBI

8. Brightness acuity / glare testing. Measures how much light glare reduces vision, a common complaint. NCBI

9. Color discrimination (extended sets). More detailed than office plates to pick up subtle color deficits. NCBI

10. Amsler home monitoring. Regular, simple home checks help detect changes (like a new wavy spot) that need re-evaluation. NCBI

C) Laboratory & Pathology / Genetics

11. Targeted genetic testing for PRPH2. Confirms the suspected cause and helps counsel family members. Panels for inherited retinal disease (IRD) usually include PRPH2. PMC+1

12. CTNNA1 sequencing when PRPH2 is negative. Looks for the less common cause linked to butterfly-shaped dystrophy. PMC

13. Broader IRD gene panel. If single-gene tests are negative, a panel can catch rare or unexpected contributors. NCBI

14. Research histopathology (rarely done clinically). Historic reports show lipofuscin-laden RPE; this is not routine care but explains the mechanism. ResearchGate

15. Family screening by genetics and imaging. Helps identify mildly affected relatives, even if they have no symptoms yet. EyeWiki

D) Electrodiagnostic Tests (measuring retinal electrical responses)

16. Full-field electroretinogram (ERG). Often normal or only mildly reduced because changes are central; a normal ERG does not rule out butterfly dystrophy. Useful to exclude wider retinal disease. NCBI

17. Multifocal ERG (mfERG). Focuses on the macula; can show reduced central responses that match the butterfly pattern. NCBI

18. Electro-oculogram (EOG). Measures RPE function; may be normal or slightly abnormal, helping to separate from conditions like Best disease. NCBI

E) Imaging Tests (core tools for diagnosis)

19. Color fundus photography. Captures the classic “butterfly wings” of macular pigment so doctors can compare over time. EyeWiki

20. Fundus autofluorescence (FAF). Key test that highlights lipofuscin. In butterfly dystrophy, FAF shows a central, radiating pattern of increased and decreased autofluorescence that maps the RPE deposits. ScienceDirect

21. Optical coherence tomography (OCT). Cross-sectional “retinal scan” that shows RPE irregularity, subtle sub-RPE material, and usually preserved retinal thickness without fluid. It helps confirm macular-centered disease. MDPI

22. Fluorescein angiography (FA). Highlights RPE window defects and blocks; useful if new vision drop suggests complications like CNV. EyeWiki

23. OCT-angiography (OCT-A). Non-dye method to screen for abnormal vessels under the macula if vision suddenly worsens. MDPI

24. Near-infrared reflectance (NIR). Can accentuate the patterned changes in and around the fovea, supporting the diagnosis. MDPI

Non-pharmacological treatments (therapies & others)

1) Low-vision rehabilitation program.
Description. A personalized program teaches you to use magnifiers, reading stands, task lighting, typoscopes, and electronic readers, with coaching to improve reading speed and daily tasks. Many patients with macular problems read better and feel more independent after structured training. Purpose. Preserve quality of life and reading independence when central vision is affected. Mechanism. Tools enlarge text, increase contrast, and optimize posture/lighting; training (including eccentric viewing) helps shift fixation to healthier retinal areas. Cochrane Library+1

2) Electronic magnification (CCTV/tablets).
Description. Closed-circuit television magnifiers, tablets, and e-readers allow large, high-contrast, adjustable text with speech options. Purpose. Faster, longer reading with less fatigue. Mechanism. Digital zoom and high-contrast display enlarge letters, which compensates for macular dysfunction. Cochrane

3) Task-specific lighting and glare control.
Description. Directional lamps, warm color temperature bulbs, matte surfaces, and brimmed hats reduce veiling glare. Purpose. Improve contrast and reduce discomfort in bright settings. Mechanism. Minimizing stray light improves the signal-to-noise ratio at the macula. avehjournal.org

4) Sunglasses with UV and high-energy visible (HEV) filtering outdoors.
Description. Quality sunglasses (UV400 with optional violet/blue-blocking tints) lower photic stress. Purpose. Comfort outdoors and theoretical reduction of light-induced RPE stress. Mechanism. Reduces short-wavelength light reaching RPE/photoreceptors; lab/animal data show blue-light phototoxicity to retinal cells; clinical protection evidence remains mixed, so this is mainly for comfort. Frontiers+2BMJ Ophthalmology+2

5) Prudent use of blue-filtering spectacles for screen work (optional).
Description. Some patients prefer mild blue-filter tints for comfort during prolonged computer use, but these lenses are not proven to prevent eye disease. Purpose. Potential subjective comfort; manage expectations. Mechanism. Filters short-wavelength light; randomized evidence shows little or no benefit for digital eye strain or sleep versus standard lenses. Health+1

6) Eccentric viewing and steady-eye strategy training.
Description. Therapists teach using a “preferred retinal locus” just off the damaged fovea. Purpose. Better reading and face recognition when the center is blurry. Mechanism. Neurovisual adaptation shifts fixation to healthier macular areas. avehjournal.org

7) Orientation & mobility training (for those with navigational difficulty).
Description. Instruction in safe navigation, contrast marking of stairs, and route planning. Purpose. Reduce falls and increase confidence outdoors. Mechanism. Compensatory strategies plus environmental modifications. avehjournal.org

8) Digital accessibility & assistive tech.
Description. Screen magnifiers, high-contrast modes, text-to-speech, and voice assistants on phones/computers. Purpose. Maintain productivity and independence. Mechanism. Software enlarges and clarifies content and replaces visual tasks with audio. PMC

9) Occupational/education accommodations.
Description. Seating, larger print, adjusted lighting, extended time, and accessible materials at work/school. Purpose. Keep working/learning effectively. Mechanism. Environmental and workflow changes reduce visual load. avehjournal.org

10) Driving assessment and counseling.
Description. Formal assessment of acuity, fields, glare, and contrast; guidance on local regulations. Purpose. Safety and legal compliance. Mechanism. Objective testing helps decide if driving is safe or if restrictions are needed. avehjournal.org

11) Smoking cessation.
Description. Stopping smoking supports retinal health and reduces oxidative stress that can worsen macular conditions. Purpose. Lower risk of additional macular damage. Mechanism. Reduces systemic and ocular oxidative stress burden. AAO Journal

12) Cardiometabolic health (blood pressure, lipids, diabetes).
Description. Control BP, cholesterol, and blood sugar with your clinician. Purpose. Support retinal microvasculature and reduce edema risks. Mechanism. Healthier perfusion and less endothelial stress benefit the macula broadly. AAO Journal

13) Eye-healthy diet (leafy greens, fish, nuts) and AREDS2-style nutrients (with caution—see below).
Description. A diet rich in lutein/zeaxanthin, omega-3s, and nuts supports macular function; AREDS2 vitamins help some AMD stages, but evidence for BPD is limited. Purpose. General retinal support. Mechanism. Antioxidants and macular pigments may reduce oxidative stress and improve macular pigment density; apply with caution since data are from AMD, not BPD. PMC+1

14) Regular monitoring with OCT and fundus autofluorescence.
Description. Scheduled imaging watches for change and detects CNV early. Purpose. Early, vision-saving treatment of complications. Mechanism. OCT shows fluid; autofluorescence maps lipofuscin/RPE stress patterns. ScienceDirect

15) Genetic counseling and (when appropriate) genetic testing.
Description. Counseling explains inheritance, options for testing PRPH2 and other IRD genes, and family planning. Purpose. Informed decisions and accurate diagnosis. Mechanism. Molecular confirmation aligns expectations and qualifies patients for trials. American Academy of Ophthalmology+2PMC+2

16) Sun/photoprotection habits.
Description. Wide-brim hats, shade seeking, and midday sun avoidance. Purpose. Comfort and potential reduction in cumulative photic stress. Mechanism. Lowers light intensity at the macula. Frontiers

17) Print/materials optimization.
Description. Use bold fonts, large print, high contrast (dark text on light matte paper), and increased spacing. Purpose. Easier reading at lower acuity. Mechanism. Improves legibility thresholds for damaged fovea. PMC

18) Psychological support/peer groups.
Description. Counseling and support groups reduce anxiety and isolation tied to vision change. Purpose. Better coping and adherence. Mechanism. Behavioral strategies and social support improve function. avehjournal.org

19) Fall-proofing the home.
Description. Mark step edges, add handrails, declutter, and increase hallway lighting. Purpose. Safety with contrast-sensitive vision. Mechanism. Environmental contrast and stability reduce risk. avehjournal.org

20) Follow-up schedule with a retina specialist.
Description. Periodic exams tailored to symptoms and imaging. Purpose. Catch CNV early and guide rehab. Mechanism. Surveillance improves timing of intervention. NCBI

Drug treatments

Important honesty first: There is no FDA-approved medicine that reverses or halts butterfly-shaped pattern dystrophy itself. When patients develop a complication such as choroidal neovascularization (CNV), retina doctors treat the CNV using FDA-approved intravitreal drugs (mainly anti-VEGF) or, rarely, photodynamic therapy. Below are the key medicines used for complications of BPD, with label-based details and typical retina dosing patterns; dosing is individualized by your clinician. PMC+1

1) Ranibizumab (Lucentis®).
Class. Anti-VEGF. Dose/time. 0.5 mg intravitreal; monthly initially, then treat-and-extend per response. Purpose. Close leaky CNV vessels and dry the macula. Mechanism. Neutralizes VEGF-A to reduce neovascular leakage and growth. Common side effects. Conjunctival hemorrhage, eye pain, transient IOP rise; rare endophthalmitis/retinal detachment. Label evidence. FDA-approved for neovascular AMD and other retinal diseases; CNV secondary to pattern dystrophy is treated analogously off-label based on pathophysiology and case data. FDA Access Data+1

2) Aflibercept 2 mg (Eylea®).
Class. VEGF-A/PlGF trap. Dose/time. 2 mg monthly for three doses, then every 8 weeks (or treat-and-extend). Purpose/mechanism. Binds VEGF-A/PlGF to suppress CNV leakage. Key risks. Endophthalmitis, IOP rise; rare arterial thromboembolic events. FDA Access Data+1

3) Aflibercept 8 mg (Eylea® HD).
Class. Higher-dose aflibercept. Dose/time. 8 mg q4 weeks x3, then q8–16 weeks as appropriate. Purpose. Longer durability in some eyes. Risks. As above. FDA Access Data

4) Faricimab (Vabysmo®).
Class. Bispecific anti-VEGF/anti-Ang-2. Dose/time. 6 mg monthly loading, then extend per label/disease. Purpose. Dual-pathway control of leakage and instability. Risks. Endophthalmitis, inflammation; contraindicated with ocular infection/active inflammation. FDA Access Data+1

5) Brolucizumab (Beovu®).
Class. Anti-VEGF single-chain antibody. Dose/time. 6 mg monthly x3, then q8–12 weeks. Purpose. CNV suppression with potential durability. Important risk. Immune-mediated retinal vasculitis/occlusion; careful patient selection and counseling required. FDA Access Data+1

6) Ranibizumab port delivery system (Susvimo®).
Class. Refillable intraocular reservoir of ranibizumab. Use. Surgical implant plus periodic refills. Purpose. Continuous anti-VEGF delivery; reduces injection frequency for some neovascular diseases. Risks. Conjunctival/implant complications; used in selected cases. FDA Access Data+1

7) Ranibizumab-nuna (Byooviz®).
Class. Ranibizumab biosimilar. Dose/time. Label parallels ranibizumab dosing in approved indications. Use in BPD. Off-label for CNV in this context. FDA Access Data+1

8) Ranibizumab-eqrn (Cimerli®).
Class. Ranibizumab biosimilar (interchangeable). Dose/time. As per ranibizumab in its indications. Use in BPD. Off-label for CNV. FDA Access Data+1

9) Bevacizumab (Avastin®).
Class. Anti-VEGF (systemic IV label for cancer). Retina use. Widely used off-label intravitreally for CNV because of cost and effectiveness. Key risks. Similar ocular injection risks; systemic label notes thromboembolic risks. FDA Access Data

10) Pegaptanib (Macugen®).
Class. VEGF-165 aptamer (historical). Retina use. FDA-approved for neovascular AMD; now rarely used but may be considered when other agents are unsuitable. Risks. Endophthalmitis, inflammation. FDA Access Data+1

11) Verteporfin (Visudyne®) photodynamic therapy (PDT) drug.
Class. Photosensitizer for PDT. Use. Occasionally considered for specific CNV lesion types when anti-VEGF is not possible or as adjunct. Risks. Post-infusion photosensitivity; infusion reactions. FDA Access Data+1

12) Dexamethasone intravitreal implant (Ozurdex®).
Class. Corticosteroid implant. Use in BPD. Not for BPD itself; occasionally used off-label if there is steroid-responsive macular edema in complex cases. Risks. IOP rise, cataract. FDA Access Data+1

13) Fluocinolone acetonide implant (Iluvien®).
Class. Long-acting corticosteroid implant. Use. Approved for DME; off-label use in select inflammatory/edematous scenarios is specialist-driven. Risks. IOP elevation, cataract. FDA Access Data+2FDA Access Data+2

14) Triamcinolone acetonide (Triesence®) intravitreal.
Class. Corticosteroid suspension. Use. Approved for several ocular inflammations and for vitrectomy visualization; may be used off-label for macular edema in select cases. Risks. IOP rise, cataract, endophthalmitis risk. FDA Access Data+1

15) Triamcinolone acetonide (Kenalog®-10) peri/intraocular (specialist use).
Class. Corticosteroid. Use. Off-label in retina when appropriate and with strict aseptic technique. Risks. As above; label warns of anaphylaxis and technique requirements. FDA Access Data

16) Carbonic anhydrase inhibitors (acetazolamide; topical dorzolamide).
Class. CAIs. Use. Sometimes tried off-label for cystoid macular edema in inherited retinal diseases; not BPD-specific, benefits vary. Risks. Paresthesias, kidney stones (oral); topical irritation. Evidence. Extrapolated from IRD edema experience; discuss carefully with your specialist. American Academy of Ophthalmology

17) Faricimab/anti-Ang-2 mechanism (context).
Note. Already listed as #4; highlighted here because dual pathway (VEGF-A + Ang-2) targets vessel leakage and stabilization in CNV physiology, which is relevant to BPD-related CNV. Risks/label. As above. FDA Access Data

18) Complement inhibitors for geographic atrophy (pegcetacoplan; avacincaptad).
Class. C3/C5 inhibitors. Use. Not for BPD itself; included to prevent confusion because patients often read about them. They treat GA in AMD, not pattern dystrophy; they do not restore lost vision. Risks. Intraocular inflammation and safety monitoring per labels. FDA Access Data+2FDA Access Data+2

19) Ranibizumab biosimilars (class note).
Note. In addition to Byooviz/Cimerli above, biosimilars follow the reference product’s mechanism and dosing in approved retinal indications; off-label CNV care mirrors ranibizumab practice where used. Regulatory context. Interchangeability and supply specifics vary. FDA Access Data

20) Photodynamic therapy combinations (visudyne + limited anti-VEGF).
Use. Rare, niche strategies when monotherapy responses are suboptimal or injections are not feasible; individualized by retina specialists. Rationale. PDT can close classic CNV components; anti-VEGF controls leakage. Caveat. Not standard for BPD—case-by-case only. FDA Access Data

Dietary molecular supplements

Important context: No supplement has proven to cure BPD. Some nutrients have supportive evidence from AMD or IRD literature; clinicians sometimes recommend them for general macular health with counseling about uncertain benefit in BPD.

1) Lutein (10 mg/day) and zeaxanthin (2 mg/day).
What it is. Macular carotenoids that concentrate in the fovea. Function/mechanism. Antioxidants that filter short-wavelength light and may support photoreceptors; evidence for AMD benefit (AREDS2), not BPD. Note. May improve macular pigment density and contrast sensitivity in some people. PMC

2) Meso-zeaxanthin (commonly 10 mg in some formulas).
Function. Complements lutein/zeaxanthin in central macula; proposed to enhance optical filtering. Evidence. Supportive in some AMD studies; BPD-specific data are lacking. PMC

3) Vitamin C (500 mg/day) & Vitamin E (400 IU/day) in AREDS2-style combinations.
Function. Antioxidant support to reduce oxidative stress at RPE. Evidence. Helped intermediate AMD risks; BPD data are absent—use as general support only after discussing with your doctor. PMC

4) Zinc (80 mg zinc oxide/day in AREDS2 patterns).
Function. Cofactor in retinal metabolism and antioxidant enzymes. Note. GI upset and copper deficiency risk; balanced formulas add copper. Evidence pertains to AMD risk reduction, not BPD. PMC

5) Copper (2 mg/day when taking high-dose zinc).
Function. Prevents copper-deficiency anemia from high-dose zinc. Context. Included in AREDS/AREDS2. PMC

6) Omega-3 fatty acids (DHA/EPA; e.g., 1 g/day).
Function. Structural support to photoreceptor membranes; anti-inflammatory effects. Evidence. Mixed in AMD; reasonable for general health with shared decision-making. PMC

7) B-complex (B6, B9, B12).
Function. Support homocysteine metabolism; vascular health is relevant to CNV risk biology. Evidence. Indirect; discuss with physician. PMC

8) Carotenoid-rich diet (spinach, kale, corn, eggs).
Function. Food-first approach to macular pigment. Evidence. Dietary patterns that raise macular pigment are plausible supports; BPD-specific trials are lacking. morancore.utah.edu

9) Resveratrol/antioxidant polyphenols (dietary sources).
Function. General oxidative-stress modulation; no BPD-specific proof. Use. As food sources rather than pills unless advised. AAO Journal

10) Safe vitamin A practices.
Function. Vitamin A is needed for phototransduction, but high-dose vitamin A is not advised in many IRDs; decisions must be individualized. Mechanism. Avoid excess retinoid load that could worsen lipofuscin biology in some IRDs (extrapolated caution). AAO Journal

Immunity-booster / Regenerative / Stem-cell / Gene-therapy” drugs

Plain truth: There are no approved regenerative or stem-cell drugs for BPD today. Below are relevant retinal therapies to understand the landscape.

1) Voretigene neparvovec (Luxturna®).
What it is. FDA-approved gene therapy for RPE65-related retinal dystrophy (not PRPH2/BPD). Dose/mechanism. Subretinal AAV delivering RPE65 to restore visual cycle in biallelic RPE65 disease. Use for BPD. Not indicated; included as a reference that gene therapy for IRDs is possible in principle. U.S. Food and Drug Administration+1

2) Complement inhibitors for AMD GA (pegcetacoplan; avacincaptad).
What they are. Intravitreal agents that slow GA area growth in AMD. Use for BPD. Not indicated; presented to prevent confusion. Mechanism. Inhibit C3 (pegcetacoplan) or C5 (avacincaptad) to modulate complement-mediated RPE damage in AMD. FDA Access Data+1

3) RPE stem-cell therapies (investigational).
Status. Early-phase trials primarily in AMD show feasibility of RPE cell replacement; BPD-specific trials are not established. Mechanism. Replace diseased RPE to support photoreceptors. Use. Research only. ICER

4) PRPH2-targeted gene therapy (investigational).
Status. Genotype-phenotype mapping and imaging cohorts are defining PARD (PRPH2-associated retinopathies) to prepare for trials. Use. Research only. PMC+1

5) Anti-angiogenic biologics (contextual immune-modulators).
Example. Faricimab (dual Ang-2/VEGF) modulates vascular leakage and inflammation pathways in CNV; used for complication treatment, not for BPD’s root cause. FDA Access Data

6) Corticosteroid implants (context).
Note. Dexamethasone/fluocinolone implants modulate intraocular inflammation/edema in other diseases; they do not regenerate the macula in BPD. Use is off-label only if a steroid-responsive edema component exists. FDA Access Data+1

Procedures/Surgeries

1) Intravitreal anti-VEGF injections.
Why done. First-line for CNV if it occurs in BPD; aim is to stop leakage, reduce fluid, and protect vision. Procedure. Office-based injection after antisepsis and anesthetic drops; repeated per response. FDA Access Data+1

2) Ranibizumab Port Delivery System (Susvimo®) implantation.
Why done. For selected neovascular conditions when frequent injections are burdensome; provides sustained ranibizumab and periodic refills. Note. Patient selection and surgical risks apply. FDA Access Data

3) Photodynamic therapy (PDT) with verteporfin.
Why done. Occasionally used for specific CNV lesion features or when anti-VEGF is unsuitable. Mechanism. Light-activated verteporfin closes abnormal choroidal vessels. FDA Access Data

4) Pars plana vitrectomy for epiretinal membrane/macular hole (if present).
Why done. Rare BPD-associated tractional problems can be peeled/repaired to improve distortion. Mechanism. Removes traction and allows foveal reconfiguration. (General retinal surgery principles; case-by-case.) NCBI

5) Cataract surgery (when cataract limits function).
Why done. Improves media clarity and brightness to maximize remaining macular function; does not treat BPD itself. Mechanism. Replaces cloudy lens with an implant, often improving contrast and enabling better imaging/follow-up. (General ophthalmic standard.) NCBI

Preventions

1. Don’t smoke; quit if you do. Reduces oxidative stress linked to macular damage. AAO Journal

2. Protect your eyes outdoors (UV/HEV sunlight control using quality sunglasses/hat). Frontiers

3. Manage blood pressure, cholesterol, and diabetes with your clinician. AAO Journal

4. Use adequate task lighting and minimize glare for safer reading and work. PMC

5. Maintain a carotenoid-rich diet (leafy greens, eggs) for macular pigment support. PMC

6. Schedule regular retina follow-ups to detect CNV early. NCBI

7. Consider genetic counseling/testing for you and, when appropriate, family. American Academy of Ophthalmology

8. Use digital accessibility features to reduce visual strain and accidents. PMC

9. Be cautious with unproven supplements and “blue-light” claims; ask your doctor. Health

10. Stay informed about clinical trials (especially PRPH2 research) through your specialist. PMC

When to see a doctor

See an eye doctor urgently if you notice new central blur, distortion (straight lines look wavy), a dark spot, sudden drop in reading vision, or new flashes/floaters, because these can signal CNV or other treatable problems. Even without new symptoms, keep your scheduled retina visits for OCT and autofluorescence imaging so subtle fluid or changes are caught early. If vision starts interfering with work, school, or driving, ask for low-vision rehabilitation and workplace accommodations right away—early training helps the most. Family members with similar symptoms should consider genetic counseling/testing to understand risks and options. PMC+2Cochrane Library+2

What to eat & what to avoid

1. Eat: dark leafy greens (spinach/kale), corn, and eggs for lutein/zeaxanthin. Avoid: relying on pills alone—food first. PMC

2. Eat: fish (e.g., salmon/sardines) 1–2×/week for omega-3s. Avoid: very high-dose fish oil without medical advice. PMC

3. Eat: nuts/legumes for healthy fats. Avoid: trans fats. PMC

4. Consider: an AREDS2-style multinutrient only after discussing with your doctor (evidence is from AMD, not BPD). Avoid: mega-doses beyond studied ranges. PMC

5. Stay hydrated and limit excessive alcohol that can worsen oxidative stress. AAO Journal

6. Balance: B-vitamin rich foods (greens, beans, fortified grains). PMC

7. Mind vitamin A: do not self-prescribe high-dose vitamin A; discuss risks/benefits. AAO Journal

8. Cook for contrast: use white plates for dark foods and vice versa; improves visibility at meals. avehjournal.org

9. Use adaptive kitchen tools (large-print labels, bold markers) to reduce mistakes. avehjournal.org

10. Keep expectations realistic: diet supports overall eye health but does not cure BPD. NCBI

Frequently asked questions

1) Is butterfly-shaped pattern dystrophy the same as AMD?
No. They can look similar, but BPD is an inherited RPE disorder (often PRPH2-related) with different natural history. Imaging and genetics help distinguish them. NCBI+1

2) Will I go blind?
Most people keep useful vision for years; some develop CNV that needs treatment. Regular monitoring is key. NCBI

3) Can glasses fix it?
Glasses correct refractive error, not RPE disease. Low-vision devices and lighting changes help function. PMC

4) Are blue-light glasses necessary?
There’s little evidence they improve eye health or symptoms versus standard lenses; use if you personally find them comfortable. Health

5) Do AREDS2 vitamins help BPD?
AREDS2 helped intermediate/late AMD risk; there’s no direct BPD proof. Consider only after discussion with your doctor. PMC

6) Should my family get tested?
BPD often follows autosomal-dominant inheritance; genetic counseling/testing can clarify risks and inform planning. American Academy of Ophthalmology

7) What imaging will I need?
OCT and fundus autofluorescence are routine; angiography or OCT-A may be used to check for CNV. ScienceDirect

8) What are the signs of CNV?
New distortion, gray spot, or sudden blur; urgent visit is needed because anti-VEGF can preserve vision. PMC

9) Are there disease-modifying drugs for BPD?
No approved drugs stop or reverse BPD. Treatments target complications; research is ongoing. NCBI+1

10) Which anti-VEGF is “best”?
Ranibizumab, aflibercept (2 mg/8 mg), faricimab, and others effectively treat CNV; choice depends on eye response, safety, cost, and visit burden. FDA Access Data+3FDA Access Data+3FDA Access Data+3

11) Is Beovu® safe?
It’s effective but carries a recognized risk of retinal vasculitis/occlusion; doctors weigh risks and benefits carefully. FDA Access Data

12) Can photodynamic therapy help?
Sometimes used when injections aren’t feasible or as adjunct for specific lesions; it’s not first-line today. FDA Access Data

13) Are stem-cell treatments available?
Not approved for BPD; RPE cell therapies remain investigational. Beware of unregulated clinics. ICER

14) Will cataract surgery worsen BPD?
Cataract surgery doesn’t treat BPD but often improves clarity; your surgeon will plan lens type and manage expectations. NCBI

15) What’s the future outlook?
Better imaging, PRPH2 natural-history studies, and gene-therapy platforms for IRDs are advancing, laying groundwork for future trials.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 07, 2025.

PDF Documents For This Disease Condition References